You are here
Retours TransAtlantiques: FerInject – lessons from the European experience
By Yves Beguin, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris
The topic of Yves Beguin’s presentation is how to treat anemia in cancer patients, particularly using intravenous iron supplementation (FerInject) instead of oral iron. He explains the differences between absolute iron deficiency in which no iron stores are present and functional iron deficiency, i.e. iron deficiency in erythroid bone marrow, which is due to iron sequestration in macrophages or increased iron requirements, for example caused by EPO therapy. Intravenous iron improves transferrin saturation and it has been shown that hematopoietic response is considerably higher with intravenous iron compared to EPO alone. With the addition of intravenous iron to EPO, EPO use can be reduced which leads to cost savings. Yves Beguin also presents data of several trials on the use of intravenous iron alone.
Yves Beguin, CHU de Liège, Belgium